{
    "hands_on_practices": [
        {
            "introduction": "Effective management of basal cell carcinoma (BCC) begins with accurate risk stratification, a process that involves synthesizing multiple clinicopathologic features to predict recurrence likelihood and guide treatment selection. This exercise  simulates this critical first step by having you apply a hypothetical, yet clinically representative, scoring system to a patient case. By translating qualitative tumor characteristics into a quantitative risk score, you will practice the objective assessment that underpins modern, evidence-based dermatologic oncology.",
            "id": "4414885",
            "problem": "A patient with a basal cell carcinoma presents with the following clinicopathologic features: maximal clinical diameter $d = 18$ mm, primary site on the nasal ala within the high-risk facial “H-zone” (H-zone), histologic subtype reported as infiltrative (morpheaform), and a documented prior recurrence after an excision performed $14$ months ago. Using a composite recurrence risk scoring system that assigns weighted points to each domain reflecting well-established recurrence predictors, define points for size, location, histology, and prior recurrence as follows:\n\nFor size (maximal clinical diameter $d$):\n$$\ns(d) = \n\\begin{cases}\n0, & d  10 \\text{ mm},\\\\\n1,  10 \\le d  20 \\text{ mm},\\\\\n3,  20 \\le d  30 \\text{ mm},\\\\\n5,  d \\ge 30 \\text{ mm}.\n\\end{cases}\n$$\n\nFor anatomic location:\n$$\nl = \n\\begin{cases}\n0,  \\text{trunk or non-critical extremity},\\\\\n2,  \\text{mask area of face excluding H-zone},\\\\\n4,  \\text{H-zone (nose, eyelids, lips, ears), perianal/genital, hands/feet}.\n\\end{cases}\n$$\n\nFor histologic subtype:\n$$\nh = \n\\begin{cases}\n0,  \\text{superficial},\\\\\n1,  \\text{nodular},\\\\\n3,  \\text{micronodular},\\\\\n4,  \\text{infiltrative/sclerosing (morpheaform)}.\n\\end{cases}\n$$\n\nFor prior recurrence status:\n$$\nr = \n\\begin{cases}\n0,  \\text{primary lesion},\\\\\n4,  \\text{recurrent lesion}.\n\\end{cases}\n$$\n\nLet the composite recurrence risk score be $S = s + l + h + r$. Categorize recurrence risk as low if $S \\le 3$, intermediate if $4 \\le S \\le 7$, and high if $S \\ge 8$. Compute $S$ for the described lesion. No rounding is required. Express the final answer as a unitless number.",
            "solution": "To compute the composite recurrence risk score $S$, we must calculate the score for each of the four domains (size, location, histology, and recurrence) and then sum them.\n\n1.  **Size Score ($s$)**: The maximal clinical diameter is given as $d = 18$ mm. According to the scoring system for size, this falls into the category $10 \\le d  20$ mm, which corresponds to a score of $s = 1$.\n\n2.  **Location Score ($l$)**: The lesion is located on the nasal ala, which is part of the high-risk facial “H-zone”. The scoring system for location assigns a score of $l = 4$ for the H-zone.\n\n3.  **Histology Score ($h$)**: The histologic subtype is reported as infiltrative (morpheaform). According to the scoring system for histology, this subtype corresponds to a score of $h = 4$.\n\n4.  **Recurrence Score ($r$)**: The lesion is documented as a recurrence. The scoring system for recurrence status assigns a score of $r = 4$ for a recurrent lesion.\n\nFinally, we sum these individual scores to compute the composite recurrence risk score, $S$:\n$$S = s + l + h + r$$\nSubstituting the scores calculated above:\n$$S = 1 + 4 + 4 + 4 = 13$$\n\nThe composite recurrence risk score $S$ for this lesion is 13. Based on the provided categories ($S \\ge 8$ is high risk), this lesion is classified as high risk, justifying an aggressive management strategy like Mohs Micrographic Surgery.",
            "answer": "$$\\boxed{13}$$"
        },
        {
            "introduction": "In dermatologic surgery, the choice of surgical margins embodies a fundamental trade-off between ensuring complete tumor removal and preserving healthy tissue to optimize functional and cosmetic outcomes. This practice problem  allows you to quantify this trade-off by calculating the precise difference in excised tissue area resulting from two different margin choices for a common BCC scenario. This calculation provides a tangible basis for understanding the critical importance of margin selection in surgical planning, especially in anatomically sensitive areas.",
            "id": "4414943",
            "problem": "A patient presents with a primary nodular Basal Cell Carcinoma (BCC) on the mid-cheek, clinically well-defined and measuring $12\\,\\mathrm{mm}$ in maximal diameter. For standard excision of low-risk nodular BCC, commonly cited margins range from $3\\,\\mathrm{mm}$ to $5\\,\\mathrm{mm}$. To quantify the trade-off in tissue conservation versus histologic clearance probability, model the excised specimen as a fusiform ellipse oriented along relaxed skin tension lines with a length-to-width ratio of $3:1$. Assume the minor axis equals the tumor diameter plus twice the chosen clinical margin, and the major axis equals three times the minor axis. Define “tissue sacrifice” as the total area of the excised specimen.\n\nUsing this geometric model, derive from first principles the expression needed to compute the difference in tissue sacrifice between choosing a $3\\,\\mathrm{mm}$ margin and a $5\\,\\mathrm{mm}$ margin for this lesion, then calculate the numerical value of this difference. Round your final numerical answer to four significant figures and express it in $\\mathrm{mm}^2$. In addition, briefly discuss the management trade-offs implicit in selecting $3\\,\\mathrm{mm}$ versus $5\\,\\mathrm{mm}$ margins for a well-defined nodular BCC on the cheek, including how margin selection relates to oncologic safety and functional-cosmetic preservation, and where Micrographic Surgery (Mohs Micrographic Surgery, MMS) fits in the decision framework. The final reported answer must be the single numerical value of the area difference only.",
            "solution": "This problem involves calculating the difference in excised tissue area based on a geometric model and discussing the clinical implications of margin selection.\n\n**Part 1: Quantitative Analysis of Tissue Sacrifice**\n\nThe area of an ellipse, which models the \"tissue sacrifice,\" is given by the formula $A = \\pi a b$, where $a$ and $b$ are the semi-major and semi-minor axes, respectively. The problem defines the major axis as length $L$ and the minor axis as width $w$. Thus, $a = L/2$ and $b = w/2$, and the area is $A = \\frac{\\pi}{4} Lw$.\n\nThe model specifies the following relationships, where $D$ is the tumor diameter and $m$ is the surgical margin:\n- Minor axis (width): $w = D + 2m$\n- Major axis (length): $L = 3w$ (from the 3:1 length-to-width ratio)\n\nSubstituting these into the area formula, we can express the area of the excised ellipse as a function of the margin $m$:\n$$A(m) = \\frac{\\pi}{4} (3w)w = \\frac{3\\pi}{4} w^2 = \\frac{3\\pi}{4} (D + 2m)^2$$\n\nWe need to calculate the difference in area, $\\Delta A$, between an excision with a margin of $m_2 = 5\\,\\mathrm{mm}$ and one with a margin of $m_1 = 3\\,\\mathrm{mm}$, for a tumor with diameter $D = 12\\,\\mathrm{mm}$.\n\n$$\\Delta A = A(m_2) - A(m_1) = \\frac{3\\pi}{4} (D + 2m_2)^2 - \\frac{3\\pi}{4} (D + 2m_1)^2$$\n\nNow, we substitute the numerical values $D = 12\\,\\mathrm{mm}$, $m_1 = 3\\,\\mathrm{mm}$, and $m_2 = 5\\,\\mathrm{mm}$:\n$$ w_1 = 12 + 2(3) = 18\\,\\mathrm{mm} $$\n$$ w_2 = 12 + 2(5) = 22\\,\\mathrm{mm} $$\n$$ \\Delta A = \\frac{3\\pi}{4} (w_2^2 - w_1^2) = \\frac{3\\pi}{4} (22^2 - 18^2) $$\n$$ \\Delta A = \\frac{3\\pi}{4} (484 - 324) = \\frac{3\\pi}{4} (160) $$\n$$ \\Delta A = 120\\pi \\, \\mathrm{mm}^2 $$\n\nUsing $\\pi \\approx 3.14159...$:\n$$ \\Delta A \\approx 376.9911... \\, \\mathrm{mm}^2 $$\n\nRounding to four significant figures, the difference in tissue sacrifice is $377.0 \\, \\mathrm{mm}^2$.\n\n**Part 2: Qualitative Discussion of Management Trade-offs**\n\nThe choice between a $3\\,\\mathrm{mm}$ and a $5\\,\\mathrm{mm}$ surgical margin for a well-defined nodular BCC exemplifies the core trade-off in dermatologic surgery between oncologic safety and functional-cosmetic preservation.\n\nA larger margin, such as $5\\,\\mathrm{mm}$, provides a higher a priori probability of achieving complete tumor removal (histologic clearance) in a single procedure. This increased oncologic safety minimizes the risk of local recurrence and the potential need for a second surgery (re-excision) if the initial pathology report shows positive margins. However, this comes at the cost of a larger surgical defect. On the face, particularly the mid-cheek, a larger defect requires a more extensive and complex repair, leading to a longer scar, greater potential for distortion of nearby anatomical structures (e.g., the eyelid or corner of the mouth), and a less favorable cosmetic outcome. The \"tissue sacrifice\" is significantly larger, as calculated above.\n\nConversely, a smaller margin, such as $3\\,\\mathrm{mm}$, prioritizes tissue conservation. This results in a smaller defect, a simpler repair, a shorter scar, and generally a better functional and cosmetic result. For a low-risk, well-defined nodular BCC, a $3\\,\\mathrm{mm}$ or $4\\,\\mathrm{mm}$ margin is often sufficient, with published cure rates well over $95\\%$. The risk of incomplete excision is slightly higher than with a $5\\,\\mathrm{mm}$ margin, but this risk is often considered acceptable given the high likelihood of success and the significant benefit of tissue preservation in a cosmetically sensitive area.\n\nMohs Micrographic Surgery (MMS) is a specialized technique that directly addresses this trade-off. In MMS, the tumor is excised with very narrow margins, and the tissue is immediately processed and examined under a microscope by the surgeon. This allows for $100\\%$ margin evaluation, as opposed to the standard bread-loafing or radial sectioning used in traditional pathology, which samples only a fraction of the margin. If any residual tumor is found, its precise location is mapped, and another thin layer of tissue is removed only from that specific area. This process is repeated until all margins are clear. MMS provides the highest possible cure rate (up to $99\\%$ for primary BCCs) while maximally conserving healthy tissue. For a BCC on the cheek, even a primary, well-defined nodular type, MMS is an excellent and often preferred management option as it obviates the need to guess the appropriate margin, thereby optimizing both oncologic clearance and the final aesthetic outcome.",
            "answer": "$$\\boxed{377.0}$$"
        },
        {
            "introduction": "The management of locally advanced or complex BCC increasingly utilizes neoadjuvant therapies, such as Hedgehog pathway inhibitors (HHIs), to reduce tumor burden before definitive surgery. This advanced exercise  challenges you to model the impact of such a strategy by calculating the expected reduction in surgical defect size based on subtype-specific tumor shrinkage. Mastering this type of predictive calculation is essential for planning complex reconstructions and counseling patients on the benefits of integrated oncologic care.",
            "id": "4414896",
            "problem": "A patient has a clinically measurable, biopsy-proven mixed-subtype basal cell carcinoma on the nasal ala with a longest clinical diameter of $1.6$ cm. Histology shows a mixture of nodular and infiltrative growth patterns. The patient is treated with a Hedgehog pathway inhibitor (HHI) for $3$ months prior to definitive surgical excision. Use the following foundational, widely accepted facts for modeling:\n\n- Under Response Evaluation Criteria in Solid Tumors (RECIST), treatment response is quantified as a fractional change in the longest tumor diameter. Published median linear shrinkage after approximately $3$ months of HHI therapy is approximately $0.35$ for nodular basal cell carcinoma and $0.20$ for infiltrative basal cell carcinoma.\n- For a mixed lesion, assume the effective fractional linear shrinkage along the longest diameter is the weighted average of the subtype-specific shrinkages, weighted by the fractional linear contributions of each subtype along the longest axis.\n- Standard surgical excision for high-risk facial basal cell carcinoma uses a fixed clinical margin of $0.6$ cm beyond the visible/clinically measurable tumor edge; assume this margin is applied equally before and after HHI, independent of shrinkage.\n- For primary closure by ellipse design, a commonly used surgical principle is that the optimal ellipse has a length-to-width ratio of approximately $3:1$. Assume the ellipse width equals the required excision width, which is the tumor diameter plus twice the clinical margin.\n\nSuppose along the longest axis the linear composition is $0.60$ nodular and $0.40$ infiltrative. Using the assumptions above, compute the expected absolute reduction in the major-axis length of the surgical ellipse (that is, the pre-HHI ellipse length minus the post-HHI ellipse length) after $3$ months of HHI therapy. Round your answer to three significant figures and express it in cm. You may discuss reconstructive implications in your reasoning, but the final reported quantity must be only the calculated reduction in major-axis length.",
            "solution": "The objective is to calculate the absolute reduction in the major-axis length of the surgical ellipse, $\\Delta L$, following neoadjuvant Hedgehog pathway inhibitor (HHI) therapy.\n\n**Step 1: Calculate the effective fractional linear shrinkage ($S_{eff}$)**\n\nThe effective shrinkage is the weighted average of the subtype-specific shrinkages. Given:\n- Fractional linear shrinkage for nodular subtype: $S_n = 0.35$\n- Fractional linear contribution of nodular subtype: $f_n = 0.60$\n- Fractional linear shrinkage for infiltrative subtype: $S_i = 0.20$\n- Fractional linear contribution of infiltrative subtype: $f_i = 0.40$\n\n$$S_{eff} = f_n S_n + f_i S_i = (0.60)(0.35) + (0.40)(0.20)$$\n$$S_{eff} = 0.21 + 0.08 = 0.29$$\nThis means the tumor's longest diameter is expected to shrink by $29\\%$.\n\n**Step 2: Define the major-axis length of the surgical ellipse**\n\nThe surgical ellipse width ($W_{ellipse}$) is the tumor diameter ($D$) plus twice the clinical margin ($M$). The major-axis length ($L_{ellipse}$) is three times the width.\n$$L_{ellipse} = 3 \\times W_{ellipse} = 3(D + 2M)$$\n\n**Step 3: Calculate the reduction in major-axis length ($\\Delta L$)**\n\nLet $D_0$ be the initial tumor diameter and $D_1$ be the post-therapy diameter.\nThe reduction in length, $\\Delta L$, is the difference between the pre-therapy length ($L_{ellipse,0}$) and the post-therapy length ($L_{ellipse,1}$).\n\n$$L_{ellipse,0} = 3(D_0 + 2M)$$\n$$L_{ellipse,1} = 3(D_1 + 2M)$$\n\n$$\\Delta L = L_{ellipse,0} - L_{ellipse,1} = 3(D_0 + 2M) - 3(D_1 + 2M)$$\n$$\\Delta L = 3D_0 + 6M - 3D_1 - 6M = 3(D_0 - D_1)$$\n\nThe reduction in tumor diameter is $D_0 - D_1 = D_0 \\times S_{eff}$. Therefore, the reduction in ellipse length is:\n$$\\Delta L = 3 \\times (D_0 \\times S_{eff})$$\nThis shows that the reduction in the final surgical defect length is three times the absolute reduction in tumor diameter, and is independent of the surgical margin value itself.\n\n**Step 4: Compute the final numerical value**\n\nGiven the initial tumor diameter $D_0 = 1.6$ cm and the calculated $S_{eff} = 0.29$:\n$$\\Delta L = 3 \\times (1.6 \\text{ cm}) \\times 0.29$$\n$$\\Delta L = 4.8 \\text{ cm} \\times 0.29 = 1.392 \\text{ cm}$$\n\nRounding the answer to three significant figures, we get:\n$$\\Delta L = 1.39 \\text{ cm}$$",
            "answer": "$$\\boxed{1.39}$$"
        }
    ]
}